Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of NT219 alone and with Erbitux in advanced solid tumors and head and neck cancer
MOH_2022-05-19_010591Phase 2Recruiting
- Sponsor
- TyrNovo Ltd.
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NT219 and cetuximab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC) and colorectal adenocarcinoma (3 arms), sponsored by TyrNovo Ltd. Primary endpoint: Safety and tolerability of NT219 alone and in combination with Erbitux. Started Mar 2022; status: recruiting.
02
Drugs
NT219cetuximab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)colorectal adenocarcinoma
Beyond the preview
Go deeper on MOH_2022-05-19_010591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-19_010591.